DIABETIC FOOT ULCERS AND POLYDEOXYRIBONUCLEOTIDE (PLACENTEX® INTEGRO MASTELLI) AS A TREATMENT FOR WOUND HEALINGMULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED, PARALLEL GROUP, CLINICAL TRIA
- Conditions
- DIABETIC FOOT ULCERS
- Registration Number
- EUCTR2007-006754-26-SI
- Lead Sponsor
- MASTELLI SR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 250
?Male and female patients must be aged between 45 and 80 years.
?Minimum schooling 5 years.
?Patient with type I or II diabetes since at least 5 years, with a stable metabolic picture
?Patient’s foot ulcer been present for a minimum of 2 weeks under the current investigator’s care
?Patient’s foot ulcer size: 1.0 cm2 and < 16.0 cm 2 at day 0
?Patient’s ulcer grade 1 or 2 of Wagner scale
?Patient’s wound free of necrotic debris and appears to be made up of healthy vascularized tissue
?Patient with adequate circulation to the foot as evidenced by: transcutaneous oxygen tension (TcPO2) measured at the dorsum of the foot exhibiting the ulcer and or >29 mmHg and/or ankle/brachial blood-pressure index >0,9
?If female, she will not be pregnant nor lactating. In case of sexual acts, she agrees to use appropriate contraceptive measures during the whole study period.
?All patients must give their written, informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
?Non-consenting patient who have not given their written consent to participation in the trial.
?History of alcohol or drug abuse.
?Pregnancy and lactation.
?Gangrene on any part of the affected foot
?Ongoing infection without treatment
?Patient’s ulcer over a Charcot deformity
?Ulcer total surface area: >16 cm2
?Patient with a non-study ulcer on the study foot that is located within 7.0 cm of the study ulcer at day 0
?Patient who at present or during the last month took part in another clinical study.
?Patient taking at present or in the last 10 days systemic cicatrizant drugs
?Patient suffering of severe malnutrition
?Patients receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents
?Signs and symptoms of neurological and/or psychiatric pathologies requiring treatment.
?Severe liver or kidney insufficiency.
?Other severe, ongoing pathologies of an internal or surgical nature.
?Proven hypersensitivity to polydeoxyribonucleotide or related drugs.
?Patient whom the Investigator deems to be unhelpful or unreliable for the purposes of the study.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The main objective of this clinical trial is to evaluate the efficacy of the polydeoxyribonucleotide (active drug) in improving the healing of diabetic foot ulcers;Secondary Objective: The second end point is to confirm the safety and the tolerability of the active compound;Primary end point(s): Complete wound closure
- Secondary Outcome Measures
Name Time Method